InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 380 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Re-Thinking Community December 10, 2021 EMA Recommends Extending the Indications for Dostarlimab October 17, 2023 Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... February 23, 2023 A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... February 6, 2023 Load more HOT NEWS Women Diagnosed with Early Breast Cancer Since 2000 Have About a... Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation... Keanu Reeves Has A Long History Of Supporting Cancer Research Physical Activity May Lessen the Effects of Chemobrain, Study Finds
